Mezzion PharmaLtd Valuation

Is A140410 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A140410 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A140410's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A140410's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A140410?

Key metric: As A140410 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A140410. This is calculated by dividing A140410's market cap by their current revenue.
What is A140410's PS Ratio?
PS Ratio	45.7x
Sales	₩20.25b
Market Cap	₩925.87b

A140410 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	43.7x
Enterprise Value/EBITDA	-63.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A140410's PS Ratio compare to its peers?

The above table shows the PS ratio for A140410 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.4x
A003090 Daewoong	0.5x	n/a	₩856.7b
A214370 Caregen	11.3x	11.1%	₩869.7b
A086450 DongKook Pharmaceutical	1x	9.4%	₩773.0b
A185750 Chong Kun Dang Pharmaceutical	0.7x	3.0%	₩1.2t
A140410 Mezzion PharmaLtd	45.7x	n/a	₩925.9b

Price-To-Sales vs Peers: A140410 is expensive based on its Price-To-Sales Ratio (45.7x) compared to the peer average (3.4x).

Price to Sales Ratio vs Industry

How does A140410's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$154.32m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$90.70m
A000230 Ildong Holdings	0.1x	n/a	US$57.16m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A140410 is expensive based on its Price-To-Sales Ratio (45.7x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A140410's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A140410 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	45.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A140410's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,500.00

-4.4%

79.2%

Medy-Tox

₩830.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩123,300.00

-10.8%

-41.6%

J2KBIO

₩54.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,490.00

-13.3%

n/a